Condition: Advanced Renal Cell Carcinoma · Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma · Sponsor: Argos Therapeutics
This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated with AGS-003 in combination with standard treatment versus subjects treated with standard treatment alone.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Study site | Scottsdale, Arizona, United States | — |
| Study site | Little Rock, Arkansas, United States | — |
| Study site | La Jolla, California, United States | — |
| Study site | Los Angeles, California, United States | — |
| Study site | Los Angeles, California, United States | — |
| Study site | San Francisco, California, United States | — |
| Study site | Aurora, Colorado, United States | — |
| Study site | Colorado Springs, Colorado, United States | — |
| Study site | Denver, Colorado, United States | — |
| Study site | Miami, Florida, United States | — |
| Study site | Tampa, Florida, United States | — |
| Study site | Atlanta, Georgia, United States | — |
+ 113 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01582672